WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that Dr. Stephen A. Hill, President and Chief Executive Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference at the Westin New York Grand Central Hotel in New York City on Wednesday, April 9, 2014 at 1:40 p.m. Eastern Time.
The presentation will be webcast and accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast may be replayed for at least two weeks following the event by accessing the Investor Calendar section of the Investor Relations page.
About Targacept
Targacept is developing an advanced clinical pipeline of NNR Therapeutics™ to treat patients suffering from serious nervous system and gastrointestinal/genitourinary diseases and disorders. Many diseases arise from abnormalities in signaling within and between the brain and other organ systems such as the bladder and the GI tract. Targacept’s NNR Therapeutics™ have the potential to normalize these signaling pathways to provide significant medical benefit. Targacept is dedicated to building health and restoring independence for patients. For more information, please visit www.targacept.com.
TARGACEPT
Building Health, Restoring Independence®
